Loading…
China Pharma Holdings, Inc. is projected to decline to $0.5413 by 2027, a -5% move from its current price of $0.57. CPHI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.5393 | $0.5694 | $0.6012 | -0.11% |
| Jul 13 | $0.5268 | $0.5688 | $0.6142 | -0.21% |
| Jul 14 | $0.5172 | $0.5682 | $0.6242 | -0.31% |
| Jul 15 | $0.5092 | $0.5676 | $0.6327 | -0.42% |
| Jul 16 | $0.5022 | $0.567 | $0.6402 | -0.52% |
| Jul 17 | $0.4959 | $0.5664 | $0.6469 | -0.63% |
| Jul 18 | $0.4901 | $0.5658 | $0.6532 | -0.73% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4901 | $0.5658 | $0.6532 | -0.73% |
| Week 2 | $0.4584 | $0.5617 | $0.6881 | -1.46% |
| Week 3 | $0.4348 | $0.5576 | $0.715 | -2.18% |
| Week 4 | $0.4153 | $0.5535 | $0.7376 | -2.90% |
| Week 5 | $0.3985 | $0.5494 | $0.7574 | -3.61% |
| Week 6 | $0.3837 | $0.5454 | $0.7753 | -4.32% |
| Week 7 | $0.3703 | $0.5414 | $0.7916 | -5.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People’s Republic of China. It provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People’s Republic of China.
China Pharma Holdings, Inc. operates in the healthcare sector. The stock is priced at $0.57 and carries a market capitalization of $23.1M, with a market rank of 4822. The current price and market positioning are framed by a bearish short-term technical backdrop, yet a longer horizon forecast envisions meaningful upside beginning in the 2030s.
Forecasts provide a year-by-year path from 2026 through 2050, with defined min, avg, max prices and ROI figures.
A major floor 36.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 54.4% above — a clean break opens room to run.
A major ceiling 117.5% above — clearing it would confirm fresh momentum.
Key CPHI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CPHI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.646 | Sell | $0.6326 | Sell |
| MA 10 | $0.653 | Sell | $0.6544 | Sell |
| MA 20 | $0.6925 | Sell | $0.6811 | Sell |
| MA 50 | $0.7166 | Sell | $0.706 | Sell |
| MA 100 | $0.6649 | Sell | $0.7803 | Sell |
| MA 200 | $1.08 | Sell | $1.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.10 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -149.16 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -18.57 | Sell |
| Bollinger %B (20,2) | 0.04 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.44 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 32.05 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.63 | Sell |
| ADX (14) | 11.08 | Neutral |
| ATR (14) | 0.04 | Info |
In the near term, the technical picture shows bearish sentiment. The RSI(14) is 40, with the 50-day simple moving average at $0.7166 and the 200-day simple moving average at $1.08. There is support at $0.57 and a resistance at $0.88. The 30-day trading range spans from $0.3986 to $0.8152, and the stock experiences high implied volatility of 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.52 | $0.57 | $0.7626 | 0% | Neutral | |
| $0.3927 | $0.5413 | $0.8067 | -5% | Neutral | |
| $0.398 | $0.583 | $0.926 | +2% | Neutral | |
| $0.3365 | $0.5192 | $0.8657 | -9% | Neutral | |
| $0.4739 | $0.7666 | $1.33 | +34% | Bullish | |
| $0.577 | $0.9756 | $1.75 | +71% | Bullish | |
| $0.4748 | $0.8374 | $1.55 | +47% | Bullish | |
| $0.4739 | $0.8704 | $1.66 | +53% | Bullish | |
| $0.4552 | $0.8696 | $1.70 | +53% | Bullish | |
| $0.395 | $0.7845 | $1.57 | +38% | Bullish | |
| $0.5732 | $1.27 | $2.80 | +123% | Bullish | |
| $0.9864 | $2.19 | $5.04 | +285% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.52 | $0.57 | $0.7065 | +0.00% |
| August 2026 | $0.4502 | $0.5455 | $0.6887 | -4.29% |
| September 2026 | $0.4214 | $0.5179 | $0.6674 | -5.07% |
| October 2026 | $0.442 | $0.5499 | $0.721 | +6.18% |
| November 2026 | $0.4598 | $0.578 | $0.7687 | +5.11% |
| December 2026 | $0.4459 | $0.5659 | $0.7626 | -2.09% |
Click any year to see its month-by-month CPHI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CPHI could reach as high as $0.7626, with a base case around $0.57 and support toward $0.52 — roughly 0% from $0.57. A consolidation phase looks the most probable path here.
Expect CPHI to range from $0.3927 to $0.8067 through 2027. The $0.5413 average target implies a -5% move from current prices. That is -5% versus the projected 2026 average. Price action looks broadly range-bound.
The CPHI price prediction for 2028 points to an average of $0.583 (low $0.398, high $0.926) — a potential gain of +2% on today's $0.57. A consolidation phase looks the most probable path here.
In 2029, CPHI is projected to trade between $0.3365 and $0.8657, averaging $0.5192 — a potential decline of -9% from today's $0.57. That is -11% versus the projected 2028 average. Price action looks broadly range-bound.
China Pharma Holdings, Inc.'s 2030 outlook centres on $0.7666, within a $0.4739 to $1.33 range. That is up +48% on the projected 2029 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, CPHI could reach as high as $1.75, with a base case around $0.9756 and support toward $0.577 — roughly +71% from $0.57. Momentum favours further upside here.
Expect CPHI to range from $0.4748 to $1.55 through 2032. The $0.8374 average target implies a +47% move from current prices. That is -14% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The CPHI price prediction for 2033 points to an average of $0.8704 (low $0.4739, high $1.66) — a potential gain of +53% on today's $0.57. Momentum favours further upside here.
In 2034, CPHI is projected to trade between $0.4552 and $1.70, averaging $0.8696 — a potential gain of +53% from today's $0.57. That is 0% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
China Pharma Holdings, Inc.'s 2035 outlook centres on $0.7845, within a $0.395 to $1.57 range. That is -10% versus the projected 2034 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2040, CPHI could reach as high as $2.80, with a base case around $1.27 and support toward $0.5732 — roughly +123% from $0.57. Buyers look set to stay in control over this stretch.
Expect CPHI to range from $0.9864 to $5.04 through 2050. The $2.19 average target implies a +285% move from current prices. That is up +72% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CPHI today (≈ 1,754.385965 CPHI) could be worth
$3,845.73
+$2,845.73 (+285%) by 2050 · US Dollar
Based on the average projected CPHI price of $2.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CPHIwould be worth at today's price.
$1,000 invested in CPHI on Jul 10, 2025 (≈ 543.478251 CPHI) would be worth
$309.78
-$690.22 (-69.0%) today · 0.31× · US Dollar
Based on a CPHI entry price of $1.84 vs. today's $0.57.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.72 | $791.67 | -20.8% |
| 1 month ago | $0.77 | $740.26 | -26.0% |
| 3 months ago | $0.65 | $876.92 | -12.3% |
| 6 months ago | $1.3 | $438.46 | -56.2% |
| 1 year ago | $1.84 | $309.78 | -69.0% |
| All time (5.0y) ago | $350 | $1.63 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CPHI forecast.
Our base-case forecast reaches $1.10 around 2040.
Implied market cap at $1.10: $44.57M
The multi-year forecast points to a transition from neutral to bullish momentum, with notable upside beginning in 2030. The 2030 forecast shows an average price of $0.7666 and a max of $1.33, delivering an estimated ROI of 34.5% and a bullish sentiment. The trajectory remains bullish through 2040 (avg $1.27, max $2.80, ROI 123.5%) and 2050 (avg $2.19, max $5.04, ROI 284.6%).
Earlier years are mixed: 2026 (avg $0.57, ROI 0, sentiment NEUTRAL), 2027 (avg $0.5413, ROI -5, sentiment NEUTRAL), 2028 (avg $0.583, ROI 2.3, sentiment NEUTRAL), and 2029 (avg $0.5192, ROI -8.9, sentiment NEUTRAL). The forecast also provides year-by-year endpoints such as 2031 (avg $0.9756, ROI 71.2), 2032 (avg $0.8374, ROI 46.9), 2033 (avg $0.8704, ROI 52.7), 2034 (avg $0.8696, ROI 52.6), and 2035 (avg $0.7845, ROI 37.6). These are estimates, not guarantees, and actual results will depend on market conditions and company performance.
Tap a question to reveal the answer.
Avg $0.7666, min $0.4739, max $1.33, ROI 34.5%, sentiment BULLISH.
Avg $1.27, min $0.5732, max $2.80, ROI 123.5%, sentiment BULLISH.
Avg $2.19, min $0.9864, max $5.04, ROI 284.6%, sentiment BULLISH.
Current price $0.57; Market cap $23.1M; Rank 4822.
2026: avg $0.57, min $0.52, max $0.7626, ROI 0, sentiment NEUTRAL. 2027: avg $0.5413, min $0.3927, max $0.8067, ROI -5, sentiment NEUTRAL. 2028: avg $0.583, min $0.398, max $0.926, ROI 2.3, sentiment NEUTRAL. 2029: avg $0.5192, min $0.3365, max $0.8657, ROI -8.9, sentiment NEUTRAL. The path then shifts to bullish in 2030 with an avg of $0.7666.
China Pharma Holdings, Inc. Community Discussion
0Share your China Pharma Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.